One shot, two protections? new trial combines dengue and chikungunya vaccines
NCT ID NCT06973772
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial will test whether giving the dengue and chikungunya vaccines at the same time is as safe and effective as giving them separately. The study involves 900 healthy adults aged 18 to 59 who have never been exposed to either virus. Researchers will measure immune responses and track any side effects over the study period.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Live attenuated dengue vaccine (serotypes 1-4) and live attenuated chikungunya vaccine (VLA1555)
What this could lead to
If successful, this could show that a single visit for both vaccines is safe and effective, simplifying protection against two mosquito-borne diseases.
What could go wrong
This is a Phase 3 trial, but results may not apply to people with prior exposure to these viruses. Co-administration could also cause more side effects or weaker immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centro Médico de São Francisco
Curitiba, Paraná, 80810-050, Brazil
-
Centro de Pesquisa Inova
Toledo, Paraná, 85902-010, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Escola da Universidade Federal de Pelotas
Pelotas, Rio Grande do Sul, 96040-010, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital São Vicente de Paulo
Passo Fundo, Rio Grande do Sul, 99010-080, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto de Pesquisa em AIDS do Estado do Rio Grande do Sul - IPARGS
Porto Alegre, Rio Grande do Sul, 91350-180, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Reumacenter
Porto Alegre, Rio Grande do Sul, 90480-000, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UBEA - União Brasileira de Educação e Assistência Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••